What smart money is saying about BioNTech
BNTX
No fund has written a full thesis on BioNTech in our archive, but 1 fund letter reports a position in it — most recently Baillie Gifford International Concentrated Growth in June 2026.
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in BioNTech on record in the archive was reported in Q2 2026, across 1 fund letter — 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 1 | 0 |
Fund activity · 1 position · 1 move
- June 2026
“We also sold our holding in the German biotechnology company BioNTech, where the abrupt announcement of the founders' departure, including the CEO, raised governance concerns we were unable to resolve.”
Read the letterBioNTech
Read the letters behind these BioNTech positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger